B+
Bull case
25%
Probability
Target price
$3.40
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
CERS
CerusCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$2.55
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$1.60
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-04
Recent news sentiment (30D)
+65.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+64.3
Score
AI commentary
Post-earnings company-source tone is constructive, supported by product growth, raised guidance, stronger IFC demand, refinancing, and BARDA expansion. Confidence remains moderate because analyst revisions, verified post-print price-reaction attribution, options data, short interest, employee sentiment, and social coverage are unavailable or insufficient in the packet. Margin compression and weaker government-contract revenue temper the bullish interpretation.
RankAlpha Sentiment Codex - 2026-08-04
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-04eventQ2 results reinforced growth and raised 2026 outlookHigh impact
Cerus reported Q2 total revenue of $63.3 million and product revenue of $57.4 million, up 10% year over year. It raised the low end of 2026 product-revenue guidance to $229-$231 million and IFC outlook to $23-$25 million; IFC volume rose approximately 20% year over year. [#SEC-8K-2026-07-30][#EARNINGS-TRANSCRIPT-2026Q2]
2026-11-02eventINT200 regulatory decision pathHigh impact
Cerus submitted the PMA for the INTERCEPT Blood System for Platelets with the INT200 illuminator as planned, with a regulatory decision anticipated in early 2027. [#SEC-8K-2026-07-30]
2026-12-31catalystIFC growth, refinancing, and BARDA support remain medium-term driversHigh impact
IFC demand is increasing, the company completed refinancing with a $30 million term-loan reduction, and the potential value of its BARDA 2024 contract increased by $21.9 million to $270.5 million. Q2 product gross margin declined to 51.4% from 55.2%, leaving conversion of growth into profitability as the key test. [#SEC-8K-2026-07-30]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-04 • Updated nightlySource: Internal modelMethodology